uniQure NV

During the six months ended June 30, 2024, no director or officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

On July 23, 2024, we announced the closing of the sale of our Lexington Facility to Genezen, and on August 1, 2024, we announced an organizational restructuring. The restructuring and the Lexington Facility sale together were the outcome of a recently completed, comprehensive review of our operations with the goals of conserving capital and streamlining our organization. As part of these changes (including the Lexington Facility sale and related employee transfers to Genezen), we expect to eliminate approximately 300 positions or 65% of our workforce.

We estimate that we will incur costs in the range of $6.5 million to $7.5 million in connection with the restructuring, consisting primarily of cash expenditures related to employee severance costs. These costs are subject to assumptions, including local law requirements, and actual expenses may differ materially from the estimates disclosed above. The restructuring is subject to the review by our Amsterdam-based works council, which is expected to be completed in the third quarter of 2024. The Company expects the restructuring to be substantially completed by the end of 2024.